Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma.
long survivors
novel agents
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2023
02 Mar 2023
Historique:
received:
07
02
2023
revised:
27
02
2023
accepted:
28
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
(1) Background: New therapeutic strategies have improved the prognosis of multiple myeloma (MM), changing the accepted view of this disease from being incurable to treatable. (2) Methods: We studied 1001 patients with MM between 1980 and 2020, grouping patients into ten-year periods by diagnosis 1980-1990, 1991-2000, 2001-2010 and 2011-2020. (3) Results: After 65.1 months of follow-up, the median OS of the cohort was 60.3 months, and OS increased significantly over time: 22.4 months in 1980-1990, 37.4 months in 1991-2000, 61.8 months in 2001-2010 and 103.6 months in 2011-2020 (
Identifiants
pubmed: 36900349
pii: cancers15051558
doi: 10.3390/cancers15051558
pmc: PMC10000382
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Epidemiol. 2015 Oct;39(5):693-9
pubmed: 26277330
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Br J Haematol. 2020 Nov;191(3):418-425
pubmed: 32367512
Oncologist. 2011;16(11):1600-3
pubmed: 21968047
Leukemia. 2007 Jan;21(1):143-50
pubmed: 17024116
J Geriatr Oncol. 2015 Sep;6(5):353-61
pubmed: 26139300
Blood. 2011 Mar 17;117(11):3025-31
pubmed: 21228328
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Blood. 2014 Sep 18;124(12):1887-93
pubmed: 25102853
Blood Cancer J. 2018 Nov 23;8(12):123
pubmed: 30470751
Nat Rev Clin Oncol. 2018 Jul;15(7):409-421
pubmed: 29686421
Bone Marrow Transplant. 1991 Feb;7(2):71-9
pubmed: 2049563
Lancet. 2020 Jan 11;395(10218):132-141
pubmed: 31836199
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
J Clin Oncol. 2010 Feb 10;28(5):830-4
pubmed: 20038719
Blood. 2014 Nov 13;124(20):3043-51
pubmed: 25293776
Leukemia. 2009 Jun;23(6):1152-7
pubmed: 19225533
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Clin Cancer Res. 2011 Apr 1;17(7):1692-700
pubmed: 21325290
Blood. 2019 Oct 17;134(16):1337-1345
pubmed: 31484647
Blood. 2008 Mar 1;111(5):2521-6
pubmed: 17901246
Blood Cancer J. 2019 Mar 18;9(4):36
pubmed: 30886139
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Lancet Oncol. 2014 Aug;15(9):931-42
pubmed: 25030467
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Haematologica. 2012 Aug;97(8):1272-7
pubmed: 22371180
Haematologica. 2018 Mar;103(3):506-513
pubmed: 29217784
Blood. 1987 Sep;70(3):869-72
pubmed: 3304465
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12
pubmed: 35623025
Br J Haematol. 2014 Mar;164(5):684-93
pubmed: 24313224
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
N Engl J Med. 2022 Jul 14;387(2):132-147
pubmed: 35660812
Haematologica. 2007 Oct;92(10):1399-406
pubmed: 18024376
N Engl J Med. 2017 Apr 6;376(14):1311-1320
pubmed: 28379796
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Br J Haematol. 2016 Oct;175(2):252-264
pubmed: 27411022
Br J Haematol. 2013 Oct;163(1):40-6
pubmed: 23889344
Haematologica. 2018 Sep;103(9):e412-e415
pubmed: 29567776
Leukemia. 2009 Dec;23(12):2210-21
pubmed: 19798094
Leukemia. 2014 Jun;28(6):1346-8
pubmed: 24418994
Br J Haematol. 2022 Feb;196(3):649-659
pubmed: 34622447
Blood. 2011 Jul 21;118(3):529-34
pubmed: 21482708
Acta Haematol. 2014;132(2):211-9
pubmed: 24662986